Imicare

Imiquimod, the active ingredient in Imicare, is an immune response modifier presented as a topical cream for cutaneous use. It stimulates local immune activity to treat virus‑related and precancerous skin lesions in adults. GNH USA supplies Imicare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imiquimod is used in dermatology to manage lesions caused by viral infection or early skin cancer. - Actinic keratosis: clears precancerous lesions on sun‑exposed skin. - Superficial basal cell carcinoma: induces regression of early‑stage skin cancer. - External genital warts (condyloma acuminata): promotes removal of HPV‑related warty growths.

Imiquimod may cause local skin reactions and, rarely, systemic effects.

Common Side Effects: - Redness at application site: mild to moderate erythema. - Itching or burning: transient discomfort during treatment. - Dryness or flaking: skin scaling around the treated area. - Swelling: localized edema. - Crusting: formation of small crusts on the lesion.

Serious or Rare Side Effects: - Severe allergic reaction: hives, swelling of face or throat. - Extensive skin ulceration: deep tissue breakdown beyond the target lesion. - Systemic flu‑like symptoms: fever, chills, malaise. - Persistent pigmentation changes: lasting hyper‑ or hypopigmentation.

Before using Imicare, consider the following safety measures. - Contraindication: Do not apply on immunocompromised skin or active infections. - Pregnancy: Avoid use unless clearly needed; discuss risks with a healthcare professional. - Breastfeeding: Caution advised; consult a physician before treatment. - Application area: Limit to prescribed lesions; avoid mucous membranes and eyes. - Monitoring: Report severe irritation, ulceration, or systemic symptoms promptly. - Store at below 25°C: keep in the original container, protect from moisture and light.

Imiquimod may interact with other topical agents and systemic immunomodulators.

Major Interactions (Avoid): - Concurrent use with other topical immunomodulators (e.g., topical steroids) may diminish efficacy. - Systemic immunosuppressants (e.g., cyclosporine) can reduce the intended immune response.

Moderate Interactions (Monitor Closely): - Co‑application of topical retinoids may increase skin irritation. - Use with other irritant creams or chemicals may exacerbate local reactions. - Caution with photosensitizing agents; increased sun sensitivity may occur.